{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:08:15Z","timestamp":1779080895903,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bulcan.2025.02.029","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T07:14:34Z","timestamp":1748416474000},"page":"838-852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["M\u00e9tastases leptom\u00e9ning\u00e9es dans le cancer du sein\u00a0\u2013\u00a0\u00c9tat des lieux et perspectives"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5287-6712","authenticated-orcid":false,"given":"Louis","family":"Larrouquere","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Clement","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Pierre","family":"Sunyach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"De Bernardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Cosset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2025.02.029_bib0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101624","article-title":"Leptomeningeal metastasis from solid tumours: EANO\u2013ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"8","author":"Le Rhun","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0255","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/neuonc\/noae103","article-title":"Leptomeningeal metastases from solid tumors: a SNO and ASCO consensus review on clinical management and future directions","volume":"26","author":"Wilcox","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0260","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/neuonc\/noac249","article-title":"Incidence proportion and prognosis of leptomeningeal disease among patients with breast versus non-breast primaries","volume":"25","author":"Lamba","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0265","doi-asserted-by":"crossref","first-page":"e20212121","DOI":"10.1084\/jem.20212121","article-title":"The anatomic basis of leptomeningeal metastasis","volume":"221","author":"Freret","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0270","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41568-024-00700-y","article-title":"The path to leptomeningeal metastasis","volume":"24","author":"Remsik","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0275","first-page":"e1236","article-title":"Leptomeningeal metastatic cells adopt two phenotypic states","volume":"5","author":"Remsik","year":"2022","journal-title":"Cancer Rep"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0280","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1126\/science.aaz2193","article-title":"Cancer cells deploy lipocalin-2\u00a0to collect limiting iron in leptomeningeal metastasis","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0285","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.cell.2017.02.025","article-title":"Complement component 3\u00a0adapts the cerebrospinal fluid for leptomeningeal metastasis","volume":"168","author":"Boire","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0290","doi-asserted-by":"crossref","first-page":"e885","DOI":"10.1002\/ctm2.885","article-title":"Single-cell RNA sequencing reveals the characteristics of cerebrospinal fluid tumour environment in breast cancer and lung cancer leptomeningeal metastases","volume":"12","author":"Ruan","year":"2022","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0295","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41523-023-00526-1","article-title":"High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease","volume":"9","author":"Im","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0300","article-title":"Leptomeningeal anti-tumor immunity follows unique signaling principles","author":"Remsik","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0305","doi-asserted-by":"crossref","first-page":"7408","DOI":"10.1038\/s41467-023-43242-x","article-title":"Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype","volume":"14","author":"Fitzpatrick","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0310","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clbc.2016.07.002","article-title":"Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis","volume":"17","author":"Morikawa","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0315","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10549-014-3054-z","article-title":"Leptomeningeal disease and breast cancer: the importance of tumor subtype","volume":"146","author":"Abouharb","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0320","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11060-017-2452-6","article-title":"Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe","volume":"133","author":"Le Rhun","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0325","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/neuonc\/noae171","article-title":"NANO-LM: an updated scorecard for the clinical assessment of patients with leptomeningeal metastases","volume":"27","author":"Le Rhun","year":"2025","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0330","doi-asserted-by":"crossref","first-page":"e207959","DOI":"10.1212\/WNL.0000000000207959","article-title":"Prognostic role of ventricular size and its dynamics in patients with leptomeningeal metastasis from solid tumors","volume":"102","author":"Le Rhun","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0335","doi-asserted-by":"crossref","first-page":"86","DOI":"10.13104\/imri.2018.22.2.86","article-title":"Comparison of contrast-enhanced T2\u00a0FLAIR and 3D T1\u00a0black-blood fast spin-echo for detection of leptomeningeal metastases","volume":"22","author":"Park","year":"2018","journal-title":"Investig Magn Reson Imaging"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0340","first-page":"vdad002","article-title":"Diagnostic accuracy of cerebrospinal fluid liquid biopsy and MRI for leptomeningeal metastases in solid cancers: a systematic review and meta-analysis","volume":"5","author":"Nakasu","year":"2023","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0345","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/jamaneurol.2014.3974","article-title":"Factors associated with the onset and persistence of post-lumbar puncture headache","volume":"72","author":"Monserrate","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0350","doi-asserted-by":"crossref","first-page":"e230039","DOI":"10.1148\/rg.230039","article-title":"Dural and leptomeningeal diseases: anatomy, causes, and neuroimaging findings","volume":"43","author":"Kurokawa","year":"2023","journal-title":"Radiographics"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0355","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/neuonc\/noaa298","article-title":"Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors","volume":"23","author":"Le Rhun","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0360","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1200\/JCO.2024.42.16_suppl.2025","article-title":"Effect of breast cancer receptor subtypes and CSF cytology status on survival for patients with leptomeningeal disease","volume":"42","author":"Niraula","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0365","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/neuonc\/noac043","article-title":"Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint EORTC BTG and RANO effort","volume":"24","author":"Le Rhun","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0370","doi-asserted-by":"crossref","first-page":"100150","DOI":"10.1016\/j.esmoop.2021.100150","article-title":"Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database","volume":"6","author":"Carausu","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0375","doi-asserted-by":"crossref","first-page":"PD4","DOI":"10.1158\/1538-7445.SABCS21-PD4-02","article-title":"Abstract PD4-02: safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: results from TBCRC049, a phase 2 non-randomized study","volume":"82","author":"Murthy","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-023-00519-0","article-title":"Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan","volume":"9","author":"Alder","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-023-00584-5","article-title":"Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and\/or leptomeningeal disease (ROSET-BM)","volume":"9","author":"Niikura","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0390","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11060-024-04788-y","article-title":"Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2\u00a0expression","volume":"170","author":"Rogawski","year":"2024","journal-title":"J Neurooncol"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0395","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","article-title":"A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor\u2013positive breast cancer","volume":"26","author":"Tolaney","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0400","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-020-0918-0","article-title":"Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis","volume":"26","author":"Brastianos","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0405","first-page":"i24","article-title":"NVTG-04\u00a0real-world outcomes with sacituzumab govitecan among breast cancer patients with central nervous system (CNS) metastases","volume":"6","author":"Morganti","year":"2024","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0410","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11060-020-03510-y","article-title":"Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival","volume":"148","author":"Chen","year":"2020","journal-title":"J Neurooncol"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0415","doi-asserted-by":"crossref","first-page":"e2400063","DOI":"10.1200\/PO.24.00063","article-title":"Clinical response to olaparib in a patient with leptomeningeal carcinomatosis in newly diagnosed breast cancer with germline BRCA2\u00a0mutation","volume":"8","author":"Shah","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0420","doi-asserted-by":"crossref","first-page":"102653","DOI":"10.1016\/j.ctrv.2023.102653","article-title":"Pharmacotherapy for leptomeningeal disease in breast cancer","volume":"122","author":"Bartsch","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0425","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM197507242930402","article-title":"Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections","volume":"293","author":"Shapiro","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0430","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.2188","article-title":"Antigen mass may influence trastuzumab concentrations in cerebrospinal fluid after intrathecal administration","volume":"110","author":"Le Tilly","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0435","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/annonc\/mdq232","article-title":"Survival of breast cancer patients with meningeal carcinomatosis","volume":"21","author":"Gauthier","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0440","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/neuonc\/noz201","article-title":"Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer","volume":"22","author":"Le Rhun","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0445","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11060-013-1244-x","article-title":"Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa","volume":"115","author":"Comte","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0450","doi-asserted-by":"crossref","first-page":"7935","DOI":"10.1002\/cam4.3422","article-title":"Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases","volume":"9","author":"Jaeckle","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0455","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13058-024-01789-7","article-title":"Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review","volume":"26","author":"Wallace","year":"2024","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0460","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/neuonc\/noac180","article-title":"Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis","volume":"25","author":"Oberkampf","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0465","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/neuonc\/noac195","article-title":"A phase I\/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: safety, efficacy, and cerebrospinal fluid pharmacokinetics","volume":"25","author":"Kumthekar","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0470","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jamaoncol.2024.1299","article-title":"Radiation therapy followed by intrathecal trastuzumab-pertuzumab for ERBB2-positive breast leptomeningeal disease: a phase 1\u00a0nonrandomized controlled trial","volume":"10","author":"Ahmed","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0475","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.22.01148","article-title":"Randomized phase II trial of proton craniospinal irradiation versus photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis","volume":"40","author":"Yang","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0480","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1634\/theoncologist.2018-0200","article-title":"Clinicopathological and treatment-associated prognostic factors in patients with breast cancer leptomeningeal metastases in relation to tumor biology","volume":"23","author":"Griguolo","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0485","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10549-024-07339-1","article-title":"Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study","volume":"206","author":"Huppert","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bulcan.2025.02.029_bib0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102384","article-title":"Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial","volume":"9","author":"Fan","year":"2024","journal-title":"ESMO Open"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125002231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125002231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T13:23:29Z","timestamp":1755869009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125002231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":49,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0007455125002231"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.02.029","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"M\u00e9tastases leptom\u00e9ning\u00e9es dans le cancer du sein\u00a0\u2013\u00a0\u00c9tat des lieux et perspectives","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}